US Patent

US11135215 — Opioid formulations

Formulation · Assigned to Camurus AB · Expires 2032-07-26 · 6y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a depot formulation of a controlled-release matrix containing buprenorphine or its salts, used in pain management and opioid maintenance.

USPTO Abstract

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weight of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Drugs covered by this patent

Patent Metadata

Patent number
US11135215
Jurisdiction
US
Classification
Formulation
Expires
2032-07-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Camurus AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.